Home > Secukinumab: a new management option for paediatric severe psoriasis

Secukinumab: a new management option for paediatric severe psoriasis

Presented By
Prof. Christine Bodemer, Neckerā€“Enfants Malades Hospital, France
Conference
EADV 2020
A new option for the management of paediatric severe chronic plaque psoriasis has just emerged with the approval of secukinumab by the European Commission (EC) for the treatment of paediatric moderate-to-severe chronic plaque psoriasis [1]. Until now, there have been limited treatment options for this condition; off-label regimens are frequently utilised with suboptimal results. Secukinumab is a fully human monoclonal antibody that inhibits interleukin (IL)-17, thus disrupting one of the key cytokines involved in the inflammatory pathway which leads to the formation of psoriatic plaques. Prof. Christine Bodemer (Neckerā€“Enfants Malades Hospital, France) reviewed the results to date of a phase 3, randomised, double-blind trial at the EADV Virtual Congress [2]. The 162 subjects between the age of 6 and 18 were randomised to 1 of 4 treatment arms: low-dose secukinumab, high-dose secukinumab, ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on